Clinical Trials Directory

Trials / Unknown

UnknownNCT05760196

Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors

A Prospective, Multicenter, High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors and GM-CSF in the Treatment of Advanced Recurrent Metastatic Head and Neck Tumors

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
56 (estimated)
Sponsor
Xiangpan Li · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is an intervention study, aiming to use high and low dose radiotherapy combined with PD-1/PD-L1 inhibitor combined with GM-CSF to observe the effect of anti-tumor immunity and long-term therapeutic response rate, and to explore a new treatment model for patients with advanced solid tumors.

Conditions

Interventions

TypeNameDescription
DRUGGM-CSFPD1 antibody is held every three weeks, and GM-CSF is used once every three weeks on days 1-14. Until the patient progresses disease or intolerable toxicity.

Timeline

Start date
2022-10-01
Primary completion
2024-12-31
Completion
2025-09-30
First posted
2023-03-08
Last updated
2023-03-08

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05760196. Inclusion in this directory is not an endorsement.

Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors (NCT05760196) · Clinical Trials Directory